Cirrhotic Patients Are at Risk for Health Care Associated Bacterial Infections

Size: px
Start display at page:

Download "Cirrhotic Patients Are at Risk for Health Care Associated Bacterial Infections"

Transcription

1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8: Cirrhotic Patients Are at Risk for Health Care Associated Bacterial Infections MANUELA MERLI,* CRISTINA LUCIDI,* VALERIO GIANNELLI,* MICHELA GIUSTO,* OLIVIERO RIGGIO,* MARCO FALCONE, LORENZO RIDOLA,* ADOLFO FRANCESCO ATTILI,* and MARIO VENDITTI *Division of Gastroenterology, Department of Clinical Medicine, Department of Infectious Diseases and Tropical Medicine, Sapienza University of Rome, Rome, Italy BACKGROUND & AIMS: Bacterial infections are a frequent and serious burden among patients with cirrhosis because they can further deteriorate liver function. We assessed the epidemiology, risk factors, and clinical consequences of bacterial infections in hospitalized cirrhotic patients. METH- ODS: In a cohort of hospitalized cirrhotic patients (n 150) referred to a tertiary care setting, all episodes of bacterial infections were recorded prospectively. Infections were classified as community-acquired (CA), health care associated (HCA), or hospital-acquired (HA). Site of infection, characteristics of bacteria, and prevalence of antibiotic resistance were reported; consequences for liver function and patient survival were evaluated. RESULTS: Fiftyfour infections were observed among 50 patients (12 CA, 22 HCA, and 20 HA). Bacterial resistance was more frequent among patients with HCA or HA infections (64% of isolates). Mortality was 37% from HA, 36% from HCA, and 0% from CA infections. Independent predictors of infection included a previous infection within the past 12 months (P.0001; 95% confidence interval [CI], ), model of end-stage liver disease score 15 (P.01; 95% CI, ), and protein malnutrition (P.04; 95% CI, ). Infectious episodes worsened liver function in 62% of patients. Patients with infection more frequently developed ascites, hepatic encephalopathy, hyponatremia, hepatorenal syndrome, or septic shock. Child class C (P.006; 95% CI, ), sepsis (P.005; 95% CI, ), and protein malnutrition (P.001; 95% CI, ) increased mortality among patients in the hospital. CONCLUSIONS: In hospitalized cirrhotic patients, the most frequent infections are HCA and HA; these infections are frequently resistant to antibiotics. As infections worsen, liver function deteriorates and mortality increases. Cirrhotic patients should be monitored closely for infections. Keywords: Sepsis; Survival; Multidrug Resistance; Nutritional Status. Bacterial infections are a frequent and severe complication in cirrhotic patients. 1 Episodes of infection are reported in 40% of hospitalized cirrhotic patients. 2 Infections are associated with a longer hospital stay and a higher risk of death; infectionrelated mortality rate, in fact, ranges between 15% and 19%. 2,3 Most of the infections in cirrhotic patients are caused by enteric bacteria. 4 This suggests that the defense mechanisms of these patients fail to prevent the microorganisms present in the intestinal lumen from reaching the systemic circulation. Sepsis favors acute decompensation of cirrhosis and may lead to hepatic encephalopathy, renal insufficiency, shock, and acute on chronic liver failure. 1 The possible risk factors for infections have been scarcely evaluated in chronic liver disease and a recent review indicated that a Child Pugh C score can be considered the only independent predictor. 5 In most of the studies, bacterial infections in cirrhotic patients are caused, in large prevalence (70% 80%), by gram-negative cocci. In the past decade, however, infections induced by gram-positive bacilli have increased, owing to longterm antibiotic prophylaxis with quinolones recommended for those patients with previous spontaneous bacterial peritonitis (SBP) episodes, 6,7 which prevents infections caused by gramnegative bacilli but not those caused by gram-positive cocci. It recently has been proposed that infections occurring in patients who have had previous recent contact with the health care system can be classified as health care associated (HCA) and may have a worse prognosis. 8 Patients with advanced liver disease frequently need to be hospitalized and therefore may be included in this risk category. No information is available about the prevalence and consequences of HCA infections in cirrhotic patients. The current study consists of a prospective investigation aimed at determining, in a large cohort of hospitalized cirrhotic patients, the following: (1) the prevalence and etiology of community-acquired (CA), HCA, and hospital-acquired (HA) bacterial infections; (2) the risk factors associated with the development of bacterial infections; (3) the short-term clinical consequences of infection; and (4) patient survival 6 months after hospital discharge. Patients and Methods Patients From October 2008 to June 2009, we consecutively enrolled all cirrhotic patients hospitalized at our University Hospital (a tertiary referral center). Diagnosis of cirrhosis was based on liver biopsy, when available, or on obvious clinical, biochemical, or ultrasonographic and endoscopic features. Exclusion criteria were a concomitant human immunodeficiency virus infection, high-dose corticosteroid treatment, and immunosuppressive therapy. The study was approved by the local Abbreviations used in this paper: CA, community-acquired; CI, confidence interval; HA, hospital-acquired; HCA, health care associated; HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome; MDR, multidrug resistant; OR, odds ratio; SBP, spontaneous bacterial peritonitis; SIRS, systemic inflammatory response syndrome by the AGA Institute /$36.00 doi: /j.cgh

2 980 MERLI ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 11 Ethical Committee Review Board, and written informed consent was signed by all the participants. Clinical Evaluation and Management Demographic, clinical, and biochemical parameters were recorded for each patient in a preformed digitalized dataset. At admission, previous relevant clinical data, such as origin of liver disease, history of alcohol abuse, ascites, encephalopathy, gastrointestinal bleeding, acute or chronic renal failure, and coexistence of other diseases, were recorded. Previous hospitalizations (within 6 mo), episodes of infections diagnosed within the past 12 months, and therapy administered during the past 4 weeks also was noted. The main cause of hospitalization was identified and basal clinical and biochemical parameters were assessed to define the severity of liver disease, renal function, and electrolyte imbalance. Mean arterial pressure, heart rate, respiratory rate, and body temperature were measured and the presence of systemic inflammatory response syndrome (SIRS) was investigated. 9 The severity of liver disease was assessed using the Child Pugh score 10 and the model of end-stage liver disease (MELD) score. 11 Hepatorenal syndrome (HRS) was diagnosed according to international criteria. 12 The nutritional status was assessed in all the patients by anthropometric measurements. 13 Complications of cirrhosis were treated according to recent guidelines. 14 Antibiotic prophylaxis was administered in patients with previous SBP or recent gastrointestinal bleeding. 15,16 Overt hepatic encephalopathy was diagnosed according to the West Haven criteria 17 and treated only when the symptoms were clinically evident. Diagnosis and Management of Infection Bacterial infections were actively looked for in all patients based on the following assessment: (1) medical history reporting symptoms of infection; (2) physical examination focused on symptoms and signs suggestive of infection; (3) laboratory tests including erythrocyte sedimentation rate, C-reactive protein level, polymorphonucleater cell count, hepatic and renal function tests, and urinary sediment; (4) analysis of the ascitic fluid when present; (5) chest radiograph; and (6) abdominal ultrasound. When a bacterial infection was suspected, further investigations (cultures of blood, urine, sputum, ascitic fluid, or purulent secretions) were performed. SBP was defined as a polymorphonucleater cell count greater than 250/mm 3 in the ascitic fluid a positive culture; pneumonia was defined as the presence of radiologic evidence of consolidation plus at least 2 of the following criteria: fever higher than 38 C or hypothermia less than 35 C, dyspnea, cough and purulent sputum, pleuritic chest pain, or signs of consolidation on physical examination. Urinary tract infections, biliary tract infections, cellulitis, and gastroenteritis were all diagnosed according to congruent symptoms and biochemical and imaging parameters following standard criteria. 18 The evidence of a positive blood culture without a recognized site of infection was defined as spontaneous bacteremia. Study Design, Follow-Up Evaluation, and Outcomes A complete patient assessment was performed at hospital admission and at discharge. If a diagnosis of infection was made during hospitalization, the patient assessment was repeated at that time. Main outcomes were modifications of the liver function, development of kidney dysfunction, development of hepatic encephalopathy, gastrointestinal bleeding, ascites, hyponatremia, length of hospital stay, and in-hospital survival. Patients were re-evaluated as outpatients at 1, 3, and 6 months or until death or liver transplant. The study was closed when the last patient enrolled had completed at least the 6-month follow-up evaluation. Definitions Infections were classified as follows. Infections were classified as HA if the diagnosis of infection was made after more than 48 hours of hospital stay. Infections were classified as HCA if the diagnosis was made within 48 hours of hospitalization in patients with any of the following criteria: (1) had attended a hospital or a hemodialysis clinic, or had received intravenous chemotherapy during the 30 days before infection; or (2) were hospitalized for at least 2 days, or had undergone surgery during the 180 days before infection; or (3) had resided in a nursing home or a long-term care facility. 8 Infections were classified as CA if the diagnosis of infection was made within 48 hours of hospitalization and the patient did not fulfill the criteria for HCA infection 8 (ie, had no recent contact with the health care system and was not hospitalized in the past 6 months). Patients with infections were treated immediately with empiric large-spectrum antibiotics, based on the site of infection and according to standard guidelines and local epidemiology. The antibiotic treatment then was modified according to the results of cultures (if available) and in case of treatment failure. All patients with infection underwent a consultation by an infectious diseases specialist with expertise in nosocomial infections. Patients were considered to have SIRS when they fulfilled the criteria established by the most recent international guidelines. Sepsis was diagnosed in the presence of SIRS and a known or highly suspected infection. Septic shock was defined as sepsis with hypotension refractory to intravascular volume loading, associated with perfusion abnormalities that required the use of inotropes. 9 The definition of a multidrug resistant (MDR) pathogen was used to describe a methicillin-resistant Staphylococcus aureus, an Acinetobacter baumannii, an extended-spectrum -lactamases producing gram-negative strain, or any bacterial isolate resistant to at least 3 classes of antimicrobial agents. 19,20 Protein malnutrition was diagnosed when the midarm muscle circumference was below the fifth percentile of the referral standard. 13 Statistical Analysis Each patient was considered only once during the first hospitalization. To evaluate liver function modifications induced by the infection, the tests performed at the time of diagnosis were compared either with recent previous results (when available) or with the liver function test at the first outpatient control after discharge (1 month), when the infection had completely resolved. All the values are reported as means standard deviations; P values less than.05 were considered significant. Data were analyzed as continuous or categoric by using the Student t test for parametric data and the Mann Whitney U test or the Wil-

3 November 2010 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS 981 coxon test for nonparametric data; the chi-square test was used for the comparison of dichotomous data. The logistic regression analysis was used to identify possible predictors of infection and in-hospital mortality. Univariate analysis (log rank) was used to identify prognostic factors of survival, and the variables selected by this analysis were included in a multivariate analysis according to a Cox regression model. The software used for the analysis was NCSS (Number Cruncher Statistical System, Kaysville, UT) Results Patients Four patients were excluded, 1 for high-dose steroid therapy and 3 because of a recurrence of cirrhosis after liver transplantation. A total of 150 patients was enrolled: 48 women and 102 men, with a mean age of years. The origin of cirrhosis was hepatitis C in 51% of cases, alcohol abuse in 19%, cryptogenetic in 15%, autoimmune in 5%, hepatitis B in 4%, and both hepatitis B and C in 3.3% of patients. Child class was A in 30%, B in 39%, and C in 31% of patients. The mean MELD score at admission was 13.5 (range, 5 40). The main reasons for hospital admission were as follows: ascites in 37 patients (25%), elective procedures in 33 (22%), suspected infection in 21 (14%), encephalopathy in 20 (13%), gastrointestinal bleeding in 12 (8%), renal failure in 5 (3%), and other reasons in the remaining 22 patients (15%). Forty-nine patients had clinical evidence of ascites at the time of hospitalization, and 82 were known to have esophageal varices (48 small and 34 large varices). Fiftytwo patients reported a previous documented infection in the past 12 months (19 urinary tract infections, 13 pneumonia, 4 spontaneous bacteremia, 4 biliary tract infections, 3 gastrointestinal, 3 skin infections, 2 SBP, and 6 in other sites). Seventeen patients received antibiotics in the preceding 30 days, 9 because of a recent infectious episode and 8 because of prophylaxis with quinolones. Thirteen patients had been treated previously with transjugular intrahepatic portosystemic shunt. Twenty-six cases had a diagnosis of hepatocellular carcinoma (HCC), 18 were within the Milan criteria, 21 and 8 exceeded the Milan criteria (3 of these patients also had portal thrombosis). The 26 patients with HCC were hospitalized either for diagnostic purposes (3 cases), to receive locoregional treatment (21 cases), or for other complications of cirrhosis (2 patients). A total of 54 episodes of bacterial infection were recorded in 50 patients (33%); 4 patients presented more than one episode of infection during hospitalization. Demographic, clinical, and biochemical characteristics of the patients with and without infection are shown in Table 1. The degree of liver impairment was significantly more severe in the patients with infection. The patients who developed an infection had significantly lower albumin levels (P.001), higher bilirubin levels (P.002), higher creatinine levels (P.001), and lower sodium levels (P.008) than those who did not. Bacterial Infections, Systemic Inflammatory Response Syndrome, and Sepsis Among the 54 episodes of infection, 12 were CA, 22 were HCA, and 20 were HA. The infections most commonly recorded were urinary tract infections (37%), pneumonia (22%), and spontaneous bacteremia (13%). Table 2 shows the frequency of the different sites of infection in the 3 epidemiologic groups. Twenty-six infections were documented microbiologically. Gram-negative organisms, particularly Escherichia coli, were isolated more frequently (62%) than gram-positive ones (38%), but gram-positive bacteria were prevalent in HA infections (64% of isolates). Blood cultures were positive in 12 episodes of infection: 3 urinary infections, 4 cases of cholangitis, 2 cases of pneumonia, 1 case of SBP, and 2 cases of spontaneous bacteremia. As shown in Table 2, 16 patients had an infection caused by MDR bacteria. Six of the 16 patients (37.5%) with MDR pathogens died during their hospital stay (3 HRS, 2 septic shock, 1 variceal bleeding). Among the 17 patients undergoing antibiotic therapy in the preceding 30 days, MDR pathogens were isolated more frequently (5 of 7 infectious episodes; P.002). SIRS was diagnosed in 43 patients and sepsis was diagnosed in 31 patients. The type of infection more often leading to sepsis was pneumonia. SIRS unrelated to infection mostly occurred in those patients undergoing invasive treatments. Risk Factors for the Development of Infection The variables examined as possible risk factors for the development of infection or sepsis are reported in Table 3. At multivariate analysis, a history of previous infection in the past 12 months, a MELD score of 15 or greater, and a diagnosis of protein malnutrition were independent predictors for infections and sepsis (Table 4). Potential risk factors that could be involved in the development of HA infections also were evaluated. The number of invasive procedures during hospitalization was significantly higher (P.02) in patients who developed HA infections (Table 5). We also found that HA infections were associated with hospitalization in rooms in which there was a need to place additional beds (P.0002) (Table 5). Clinical Features A worsening of liver function frequently was observed in patients with infection, especially in those with sepsis. The Child Pugh score deteriorated in 62% of cases with infection (mean increase in Child score, ; range, 1 2) and in 71% of patients with sepsis (mean increase in Child score, ; range, 1 4), whereas the MELD score in the same patients showed a mean increase of (range, 1 4) in patients with infection and of (range, 1 12) in those with sepsis. The parameters that deteriorated more often were as follows: bilirubin ( mg/dl), albumin ( g/dl), creatinine ( mg/dl), and serum sodium ( meq/l) levels, respectively. Moreover, episodes of ascites, hepatic encephalopathy, hyponatremia, HRS, and septic shock were more frequent in patients with infection as compared with those who were not infected (Table 6). Outcomes Overall in-hospital mortality was 12%; 14 patients with and 4 patients without infection died (28% vs 4%; P.00007). The mortality rate was higher in the patients with sepsis (12 of 31; 38%) than in those with infection but no sepsis (2 of 19, 10%; P.00000).

4 982 MERLI ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 11 Table 1. Demographic, Clinical, and Biochemical Characteristics of Patients Included in the Study Classified According to the Presence of Infection During Their Hospitalization Variables Patients without infections (n 100) Patients with infections (n 50) P value Age, y Male/females 64/36 38/12.1 Active alcohol abusers, n (%) 21 (21) 14 (28).6 Origin of liver disease Alcohol, n (%) 19 (19) 10 (20).8 HCV-related, n (%) 56 (56) 21 (42).1 HBV-related, n (%) 6 (6) 5 (10).37 Other, n (%) 19 (19) 14 (28).09 Main cause of admission Elective procedure, n (%) 31 (31) 2 (4).001 Ascites, n (%) 30 (30) 7 (14).001 Suspected infection, n (%) 0 (0) 21 (42).001 Encephalopathy, n (%) 11 (11) 9 (18).16 Gastrointestinal bleeding, n (%) 9 (9) 3 (6).4 Renal failure, n (%) 2 (2) 3 (6).14 Other, n (%) 17 (17) 5 (10).15 HCC, n (%) 20 (20) 7 (14).36 MELD score Child Pugh score Mean arterial pressure, mm Hg Heart rate, beats/min Respiratory rate, breaths/min Temperature, 37.5 C 6 (6) 37 (74).016 White blood cells, cell/mm Hemoglobin level, g/dl Platelets, num/mm Alanine aminotransferase level, IU/L Serum bilirubin level, mg/dl Serum albumin level, mg/dl International normalized ratio Serum creatinine level, mg/dl Blood urea nitrogen level, mg/dl Serum sodium level, mmol/l Serum potassium level, mmol/l Sedimentation rate, mm/h HCV, hepatitis C virus; HBV, hepatitis B virus. Patient mortality was related to the epidemiology of infection: patients with HA infections, in fact, had a mortality rate (37%) similar to that of patients with HCA infections (36%), whereas none of the patients with CA infections died (P.046). Univariate analysis showed that sepsis (P.00000), bacterial infections (P.00002), MELD score of 15 or greater (P.03), Child class C (P.00004), protein malnutrition (P ), development of antibiotic resistance (P.00009), and hyponatremia (P.002) were related significantly to mortality. Multivariate analysis selected Child class C (P.006; odds ratio [OR], 6.3; 95% confidence interval [CI], ), sepsis (P.0056; OR, 6.01; 95% CI, ), and protein malnutrition (P.0004; OR, 10.44; 95% CI, ) as independent predictors of in-hospital death. Causes of in-hospital death in patients with infections were HRS (6 patients), septic shock (5 patients), hemorrhagic shock (2 patients), severe arrhythmia causing cardiovascular arrest (1 patient). All of the 4 patients who died without infection died of end-stage liver failure, and 3 of them also had a diagnosis of advanced HCC. The overall mortality in the following 6 months also was evaluated. The mortality rate at 3 months was 34% versus 6%, and at 6 months was 50% versus 11% in patients with infection as compared with those without infection (Supplementary Figure 1). The main causes of death after hospital discharge were end-stage liver failure (7 patients), variceal bleeding (4 patients), renal failure (4 patients), septic shock (2 patients), and myocardial infarction (1 patient); 5 patients underwent liver transplantation. Discussion Cirrhosis presently may be considered one of the most common immunodeficiency-acquired conditions and previous studies reported an infection rate of 40% to 50% among hospitalized cirrhotic patients, with consequent significant morbidity and mortality rates. 2,5 In the present study, we found the following: (1) the large majority of bacterial infections in hospitalized cirrhotic patients are HCA or HA; (2) the high prevalence of these epidemiologic categories contributes to a higher

5 November 2010 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS 983 Table 2. Characteristics of the 54 Episodes of Infections According to the Epidemiology Classification CA (n 12) HCA (n 22) HA (n 20) Sites of infection Urinary tract infections, n (%) 4 (33) 4 (18) 9 (45) Pneumonia, n (%) 3 (25) 5 (23) 4 (20) Spontaneous bacteriemia, n (%) 1 (8) 4 (18) 2 (10) Spontaneous bacterial 1 (8) 2 (9) 1 (5) peritonitis, n (%) Biliary tract infections, n (%) 1 (8) 2 (9) 1 (5) Other infections, n (%) (eg, 2 (16) 4 (18) 2 (10) skin, gastrointestinal, lymphangitis, bursitis) Microbiologically documented 4 (33) 11 (50) 11 (55) infections Isolated pathogens Staphylococcus aureus Coagulase-negative Staphylococci Enterococcus faecalis Enterobacteriaceae (E coli, Klebsiella, Proteus) MDR 2 (16) 9 (41) 5 (23) prevalence of antibiotic-resistant strains and a worse outcome; (3) in addition to the severity of the liver disease, protein malnutrition is an important independent risk factor for the development of infections in cirrhosis; and (4) infection and sepsis induce liver deterioration and increase the risk of hepatic encephalopathy, renal failure, hyponatremia, and mortality in cirrhotic patients. In our experience, the most common sites of infection were the urinary (35%) and the lower respiratory (22%) tracts. These latter infections were those more frequently leading to a sepsis syndrome. In all the patients hospitalized with clinical evidence of ascites (49 cases), the peritoneal fluid was analyzed for neutrophil cell count and bacterial culture, and 4 (8%) patients Table 3. Variables Associated With Infection at Univariate Analysis in the Patients Included in the Study Variables Patients without infections (100) Patients with infections (50) P value Previous hospitalizations 37 (37) 33 (66).006 (past 6 months), n (%) Previous infections (past 26 (26) 26 (52) months), n (%) Child Pugh class C, n (%) 24 (24) 22 (44).012 MELD score, 15,n(%) 25 (25) 25 (50).002 Protein malnutrition, n (%) 19 (19) 26 (52).001 Transjugular intrahepatic 5 (5) 12 (24).02 portosystemic shunt, n(%) Recent gastrointestinal 6 (6) 4 (8).64 bleeding ( 7 d),n(%) Antibiotic therapy in the 9 (9) 8 (16).2 preceding 30 days Diabetes, n (%) 29 (29) 16 (32).8 Table 4. Variables Independently Associated With Infection and Sepsis at Multivariate Analysis Previous infections (past 12 months) Infections OR, % CI, P.000 MELD score, 15 OR, % CI, P.001 Protein malnutrition OR, 4 95% CI, P.004 Sepsis OR, % CI, P.007 OR, % CI, P.001 OR, 4 95% CI, P.004 had a diagnosis of SBP, a rate similar to that reported previously in other Italian studies. 3 Enteric gram-negative cocci were the microorganisms more frequently isolated, whereas gram-positive ones were more frequent in the HA infection group. It has recently been proposed that antibiotic resistances are increasing in hospitalized cirrhotic patients and this has been attributed to the larger diffusion of quinolone prophylaxis for SBP. 6 In the present study we found a consistent (64%) number of MDR pathogens among the isolates. This high prevalence was probably related to the great number of HCA and HA infections that were diagnosed in our series, because the patients with advanced liver disease frequently are in need of hospital care. Previous studies, performed on noncirrhotic patients, showed that HA and HCA infections are caused more frequently by antibiotic-resistant bacteria and are associated with a more severe clinical course than CA infections. 8,22 A different empiric treatment for this new epidemiologic category has been suggested. The present prospective and observational study reports data on HCA infections in cirrhotic patients. We confirm that, as in other categories, in cirrhotic patients HCA infections also are similar to HA infections with regard to the prevalence of antibioticresistant pathogens, severe clinical course, and unfavorable outcome (in-hospital mortality in our series was 37% in HCA, 36% in HA, and none of the patients with CA infections died). In a recent meta-analysis, only the severity of liver disease has been Table 5. Prevalence of Factors That May Be Involved in the Development of HA Infections Variables Patients without infections (100) Patients with HA infections (16) P value Patients undergoing 66 (74) 14 (75).08 invasive procedures, n(%) Invasive procedures, number per patient a Patients hospitalized in a room with an additional bed, n (%) 19 (19) 10 (62).001 a Invasive procedures were as follows: paracentesis, dialysis, urinary catheter, endoscopic variceal ligation, sclerotherapy, endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, locoregional treatments of HCC, and placement of a transjugular intrahepatic portosystemic shunt.

6 984 MERLI ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8, No. 11 Table 6. Clinical Complications in 150 Cirrhotic Patients With and Without Infections and With and Without Sepsis During Their Hospitalization Patients with infection (50) Patients without infection (100) P value Patients with sepsis (31) Patients without sepsis (119) P value HRS type 1, n (%) 7 (14) (16) 2 (1.6).001 HRS type 2, n (%) 4 (8) 2 (2).05 4 (13) 2 (1.6).004 Hepatic encephalopathy, n (%) 19 (38) 15 (15) (35) 23 (19).05 Ascites, n (%) 33 (66) 51 (51) (74) 61 (51).02 Variceal bleeding, n (%) 7 (14) 6 (6).2 5 (16) 8 (6.7).2 Hyponatremia, n (%) 19 (38) 14 (14) (42) 8 (6.7).001 Shock, n (%) 6 (12) (19) In-hospital mortality, n (%) 14 (28) 4 (4) (38) 6 (5).001 rewarded as a reliable risk factor for infections and sepsis. 5 When the factors associated with both these conditions were examined, we could confirm that the severity of the liver disease (indicated by a MELD score of 15) is a good predictor, but we also found that additional parameters (a previous episode of infection in the past 12 months and protein malnutrition) may allow identification of a subgroup of cirrhotic patients at high risk of infection. All these parameters are easy to identify at hospital admission through the clinical history, simple anthropometric measurements, and biochemical data. Malnutrition is known to be a negative prognostic factor for in-hospital morbidity and mortality in cirrhotic patients 23 and increases the rate of infection in liver recipients. 24 As previously reported, the consequences of infection/sepsis in cirrhotic patients are highly detrimental. 3 The liver function deteriorated in about two thirds of the patients who developed an infection: these patients showed a worsening of the main indicators of hepatic function (bilirubin and albumin) and a higher risk of encephalopathy, ascites, renal dysfunction, hyponatremia, and hemodynamic shock. The mechanism through which infections induce a further deterioration of liver function in cirrhotic patients has not been investigated extensively as yet. Infections, and especially sepsis, are accompanied by a downright cytokine storming, mostly interleukin-6 and tumor necrosis factor-. These latter are the major hepatic triggers for the production of acute-phase proteins. 25 It is conceivable that a cirrhotic liver facing an infection or an increased endotoxin blood level may be overwhelmed by an increased demand of acute-phase reaction protein, 26 and this may lead to an exhaustion of the hepatocytes reserve function. It is worth noting that the in-hospital mortality rate was higher in those patients who had an episode of infection during hospitalization. Moreover, survival was worse in this group even for those who were discharged from the hospital. The main causes of death in this setting were liver failure, variceal bleeding, and renal failure: the episode of infection by deteriorating liver function seems to accelerate the natural history of the disease. In conclusion, the results of our study show that the majority of infections in hospitalized cirrhotic patients are HCA. Severe liver disease, malnutrition, and infection in the past 12 months are parameters that identify patients at higher risk. Because infection and sepsis are highly detrimental in hospitalized patients with cirrhosis and frequently are caused by resistant pathogens the identification of the criteria to select a high-risk group may help in planning a different empiric antibiotic approach in this category. Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at and at doi: / j.cgh References 1. Gustot T, Durand F, Lebrec D, et al. Severe sepsis in cirrhosis. Hepatology 2009;50: Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001;33: Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infection in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007;45: Wong F, Bernardi M, Balk R, et al. International Ascites Club. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005;54: Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007; 102: Fernández J, Navasa M, Gómez J, et al. Bacterial Infection in cirrhosis: epidemiological changes with invasive procedures and Norfloxacin prophylaxis. Hepatology 2002;35: Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and haemorrhage. Gastroenterology 2006;131: Venditti M, Falcone M, Corrao S, et al. Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospitalacquired pneumonia. Ann Intern Med 2009;150: Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: Crit Care Med 2008;36: Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and

7 November 2010 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS 985 treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56: Merli M, Riggio O, Dally L. Policentrica Italiana Nutrizione Cirrosi. Does malnutrition affect survival in cirrhosis? Hepatology 1996; 23: Garcia-Tsao G, Lim JK. Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension. Am J Gastroenterol 2009;104: Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49: Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;43: Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36: Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55: Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)- producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003;63: Mazzaferro V, Regalio E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334: Friedman ND, Kaye KS, Stout JE, et al. Health care associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137: Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int 2009;29: Merli M, Giusto M, Gentili F, et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver International 2010;30: Trautwein C, Boker K, Manns MP. Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanism. Gut 1994;35: Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340: Reprint requests Address requests for reprints to: Professor Manuela Merli, MD, Gastroenterologia II, Dipartimento di Medicina Clinica, Sapienza Università di Roma, Viale dell Università 37, Rome, Italy. manuela.merli@uniroma1.it; fax: (39) Acknowledgments The authors thank Mrs Maria Teresa Barbieri for assistance with the English revision. Conflicts of interest The authors disclose no conflicts. Funding Supported by a research grant C26FO9BMAN from Sapienza University of Rome.

8 November 2010 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS 985.e1 Supplementary Figure 1. Survival in 150 hospitalized cirrhotic patients according to the presence of infection. Curves were estimated using the Kaplan Meier method. A period of 6-months follow-up was examined. Patients with diagnosis of infection at the time of enrollment showed a higher rate of mortality (P.0001).

Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT

Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT 20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit

More information

Infections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital

Infections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic

More information

Bacterial infections are a frequent and lifethreatening

Bacterial infections are a frequent and lifethreatening AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 63, NO. 5, 2016 LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION An Empirical Broad Spectrum Antibiotic Therapy in Health-Care Associated

More information

Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis

Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis ORIGINAL ARTICLE 2018 Mar 6. [Epub ahead of print] Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis Jungok Kim 1, Cheol-In

More information

EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem

EDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,

More information

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis

Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis 168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department

More information

INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS

INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many

More information

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments

More information

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:

More information

Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis

Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:260 265 Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis PUNEETA TANDON*,

More information

Management of Cirrhosis Related Complications

Management of Cirrhosis Related Complications Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this

More information

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for

More information

Ascites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites

Ascites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA

More information

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal

More information

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS

PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of

More information

Causes of Liver Disease in US

Causes of Liver Disease in US Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,

More information

Chronic Hepatic Disease

Chronic Hepatic Disease Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver

More information

Online Supplement for:

Online Supplement for: Online Supplement for: INFLUENCE OF COMBINED INTRAVENOUS AND TOPICAL ANTIBIOTIC PROPHYLAXIS ON THE INCIDENCE OF INFECTIONS, ORGAN DYSFUNCTIONS, AND MORTALITY IN CRITICALLY ILL SURGICAL PATIENTS A PROSPECTIVE,

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

JMSCR Vol 05 Issue 11 Page November 2017

JMSCR Vol 05 Issue 11 Page November 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients

More information

Care of the Patient With Cirrhosis

Care of the Patient With Cirrhosis REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while

More information

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,

More information

Septic Shock. Rontgene M. Solante, MD, FPCP,FPSMID

Septic Shock. Rontgene M. Solante, MD, FPCP,FPSMID Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage

More information

A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy

A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:613 616 A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy OLIVIERO RIGGIO,* LORENZO RIDOLA,* CHIARA PASQUALE,* ILARIA

More information

Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL

Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure

More information

CIRRHOSIS Definition

CIRRHOSIS Definition Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous

More information

ISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis

ISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions

More information

CLIF Consortium. Protocol of the CLIF Acute-oN-ChrONic LIver Failure in Cirrhosis (CANONIC) Core Study

CLIF Consortium. Protocol of the CLIF Acute-oN-ChrONic LIver Failure in Cirrhosis (CANONIC) Core Study CLIF Consortium Protocol of the CLIF Acute-oN-ChrONic LIver Failure in Cirrhosis (CANONIC) Core Study Case Report Form (Final) Center: Investigator: Investigator s Signature: The highlighted information

More information

Cirrhosis is an important cause of morbidity and mortality

Cirrhosis is an important cause of morbidity and mortality CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:487 493 Role of Fluoroquinolones in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis: Meta-Analysis ROHIT LOOMBA,* ROBERT WESLEY, ANDREW BAIN,*

More information

JOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013

JOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS

More information

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,

More information

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1129 1134 ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT Spleen Enlargement on Follow-Up Evaluation: A Noninvasive Predictor of Complications of Portal

More information

Outpatient treatment in women with acute pyelonephritis after visiting emergency department

Outpatient treatment in women with acute pyelonephritis after visiting emergency department LETTER TO THE EDITOR Korean J Intern Med 2017;32:369-373 Outpatient treatment in women with acute pyelonephritis after visiting emergency department Hee Kyoung Choi 1,*, Jin-Won Chung 2, Won Sup Oh 3,

More information

Title: CLIF-C ACLF score is a better mortality. patients with Acute on Chronic Liver Failure admitted to the ward

Title: CLIF-C ACLF score is a better mortality. patients with Acute on Chronic Liver Failure admitted to the ward Title: CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on Chronic Liver Failure admitted to the ward Authors: Rita Barosa, Lídia Roque Ramos, Marta Patita,

More information

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa

More information

King Abdul-Aziz University Hospital (KAUH) is a tertiary

King Abdul-Aziz University Hospital (KAUH) is a tertiary Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors

More information

Beta-blockers in cirrhosis: Cons

Beta-blockers in cirrhosis: Cons Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory

More information

Initial approach to ascites

Initial approach to ascites Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective

More information

Supplementary Digital Content

Supplementary Digital Content Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy

More information

Management of the Cirrhotic Patient in the ICU

Management of the Cirrhotic Patient in the ICU Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes

More information

Liver failure &portal hypertension

Liver failure &portal hypertension Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.

More information

Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:

Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,

More information

REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.

REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D. REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole

More information

Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome

Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident

More information

Organ allocation for liver transplantation: Is MELD the answer? North American experience

Organ allocation for liver transplantation: Is MELD the answer? North American experience Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and

More information

Hepatorenal Syndrome

Hepatorenal Syndrome Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot

More information

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008 The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to

More information

SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES

SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES SERUM CYSTATIN C CONCENTRATION IS A POWERFUL PROGNOSTIC INDICATOR IN PATIENTS WITH CIRRHOTIC ASCITES YEON SEOK SEO, 1 SOO YOUNG PARK, 2 MOON YOUNG KIM, 3 SANG GYUNE KIM, 4 JUN YONG PARK, 5 HYUNG JOON YIM,

More information

The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis

The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.106 The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis Jong Hoon Kim, June Sung Lee, Seuk Hyun Lee, Won Ki

More information

Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis

Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;xx:xxx 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53

More information

BETA-BLOCKERS IN CIRRHOSIS.PRO.

BETA-BLOCKERS IN CIRRHOSIS.PRO. BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis

More information

The effect of bacterial infections in cirrhotic patients with esophageal variceal bleeding

The effect of bacterial infections in cirrhotic patients with esophageal variceal bleeding 364 Gan Z-H, et al., 2014; 13 (3): 364-369 ORIGINAL ARTICLE May-June, Vol. 13 No. 3, 2014: 364-369 The effect of bacterial infections in cirrhotic patients with esophageal variceal bleeding Zuo-Hua Gan,*,,

More information

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287

More information

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta. VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic

More information

Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis

Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Original Article Page 1 of 9 Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis Rui Sun*, Xingshun Qi* #, Deli Zou, Xiaodong Shao, Hongyu Li, Xiaozhong

More information

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015 ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural

More information

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes

More information

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.

More information

following the last documented transfusion; thereafter, evaluate the residual impairment(s).

following the last documented transfusion; thereafter, evaluate the residual impairment(s). Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood

More information

Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis

Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis Diagnostic Problems in Hepatology 181 Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis Carmen Sendra, MD 1 Javier Ampuero, MD, PhD 1,2 Álvaro

More information

Complications of Cirrhosis

Complications of Cirrhosis Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency

More information

The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality

The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality Sammy Saab, 1,2 Carmen Landaverde, 3 Ayman B Ibrahim, 2 Francisco Durazo, 1,2 Steven Han, 1,2 Hasan

More information

Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis

Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis Original Article Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis Lichun Shao 1 *, Bing Han 1 *, Shu An 2, Jiaxin Ma 1, Xiaozhong Guo 3, Fernando Gomes Romeiro 4, Andrea Mancuso

More information

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if: Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned

More information

Michele Bettinelli RN CCRN Lahey Health and Medical Center

Michele Bettinelli RN CCRN Lahey Health and Medical Center Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration

More information

Optimal management of ascites

Optimal management of ascites Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference

More information

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS

More information

Hepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover

Hepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS

More information

Program Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.

Program Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship

More information

CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?

CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The

More information

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

Decompensated chronic liver disease

Decompensated chronic liver disease Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation

More information

Early Klebsiella pneumoniae Liver Abscesses associated with Pylephlebitis Mimic

Early Klebsiella pneumoniae Liver Abscesses associated with Pylephlebitis Mimic Early Klebsiella pneumoniae Liver Abscesses associated with Pylephlebitis Mimic Hepatocellular Carcinoma Chih-Hao Shen, MD 3, Jung-Chung Lin, MD, PhD 2, Hsuan-Hwai Lin, MD 1, You-Chen Chao, MD 1, and Tsai-Yuan

More information

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I

More information

Renal dysfunction is a common complication of

Renal dysfunction is a common complication of GASTROENTEROLOGY 2013;145:1280 1288 New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection FLORENCE WONG, 1 JACQUELINE G. O LEARY,

More information

Polmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma

Polmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma Polmoniti: Steroidi sì, no, quando Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma Number of patients Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive

More information

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for: Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona

More information

Conflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.

Conflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension. Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications

More information

Cirrhosis Complications

Cirrhosis Complications Cirrhosis Complications and Spontaneous Bacterial Peritonitis While these complications greatly increase mortality from decompensated cirrhosis, effective treatment is possible with early diagnosis. Vigilant

More information

An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery

An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery The American Journal of Surgery (2012) 203, 589 593 North Pacific Surgical Association An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery Marlin Wayne Causey,

More information

Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis

Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis GASTROENTEROLOGY 2011;140:488 496 Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis MARTA MARTÍN LLAHÍ,*,, MÓNICA GUEVARA,*,, ALDO TORRE,*,, CLAUDIA FAGUNDES,*,, TEA RESTUCCIA,*,,

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:689 695 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated

More information

Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide

Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death

More information

Learning Objectives. After attending this presentation, participants will be able to:

Learning Objectives. After attending this presentation, participants will be able to: Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation

More information

Thirty-day hospital readmission rates frequently are used as

Thirty-day hospital readmission rates frequently are used as CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:254 259 Incidence and Predictors of 30-Day Readmission Among Patients Hospitalized for Advanced Liver Disease KENNETH BERMAN,*, SWETA TANDRA,* KATE FORSSELL,

More information

TREBALL DE RECERCA. Facultat de Medicina Departament de Medicina Hospital de la Santa Creu i Sant Pau

TREBALL DE RECERCA. Facultat de Medicina Departament de Medicina Hospital de la Santa Creu i Sant Pau TREBALL DE RECERCA INSUFICIÈNCIA RENAL I MORTALITAT DELS PACIENTS CIRRÒTICS AMB PERITONITIS BACTERIANA ESPOTÀNIA I BAIX RISC DE MORTALITAT NO TRACTATS AMB ALBÚMINA. Facultat de Medicina Departament de

More information

Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC

Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver

More information

Chronic liver failure affects multiple organ systems and

Chronic liver failure affects multiple organ systems and ORIGINAL ARTICLES Model for End-Stage Liver Disease (MELD) Predicts Nontransplant Surgical Mortality in Patients With Cirrhosis Patrick G. Northup, MD,* Ryan C. Wanamaker, MD, Vanessa D. Lee, MD, Reid

More information

Community-Acquired Pneumonia OBSOLETE 2

Community-Acquired Pneumonia OBSOLETE 2 Community-Acquired Pneumonia OBSOLETE 2 Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with respect to appropriate

More information

Terlipressin: An Asset for Hepatologists!

Terlipressin: An Asset for Hepatologists! DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent

More information

LIVER, PANCREAS, AND BILIARY TRACT

LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1157 1161 LIVER, PANCREAS, AND BILIARY TRACT Delayed and Unsuccessful Endoscopic Retrograde Cholangiopancreatography Are Associated With Worse Outcomes

More information